Navigation

oxymetazoline, ophthalmic (Visine L.R.)

 

Classes: Decongestants, Ophthalmic

Dosing and uses of Visine L.R. (oxymetazoline ophthalmic)

 

Adult dosage forms and strengths

ophthalmic drops

  • 0.025%

 

Relief of Eye Redness

Temporary relief of ocular redness caused by irritation & relief of burning or irritation caused by dry eyes

1-2 gtt to affected eye q6hr PRn

Not to exceed 72 hours of use

 

Administration

Remove contact lenses before use

Do not use if this solution changes color or becomes cloudy

Do not touch tip of container to any surface to avoid contamination

Replace cap after each use

 

Pediatric dosage forms and strengths

ophthalmic drops

  • 0.025%

 

Relief of Eye Redness

<6 years

  • Safety and efficacy not established

>6 years

  • 1-2 gtt to affected eye q6hr PRN
  • Not to exceed 72 hours of use

 

Administration

Remove contact lenses before use

Do not use if this solution changes color or becomes cloudy

Do not touch tip of container to any surface to avoid contamination

Replace cap after each use

 

Visine L.R. (oxymetazoline ophthalmic) adverse (side) effects

Frequency not defined

Transient irritation/burning/stinging

 

Warnings

Contraindications

Hypersensitivity

 

Cautions

Discontinue and seek medical advice if the following occur: eye pain, changes in vision, redness or irritation of the eye lasts >72 hr

May exacerbate glaucoma; use caution

 

Pregnancy and lactation

Pregnancy category: C

Lactation: Not known if distributed in milk

Pregnant or breastfeeding patients should seek advice of health professional before using OTC drugs

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Visine L.R. (oxymetazoline ophthalmic)

Mechanism of action

May stimulate a-adrenergic receptors of the sympathetic nervous system

May produce mydriasis when applied to the conjunctiva, but this effect is usually minimal with the concentrations used as ocular decongestants